Mirae Asset Global Etfs Holdings Ltd. Trevi Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $56.2 Billion
- Q3 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 40,625 shares of TRVI stock, worth $460,281. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,625
Previous 41,545
2.21%
Holding current value
$460,281
Previous $227,000
59.91%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TRVI
# of Institutions
174Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...